A New Splice Variant of the Mouse SIRT3 Gene Encodes the Mitochondrial Precursor Protein by Cooper, Helen M. et al.
A New Splice Variant of the Mouse SIRT3 Gene Encodes
the Mitochondrial Precursor Protein
Helen M. Cooper
1., Jing-Yi Huang
2., Eric Verdin
2, Johannes N. Spelbrink
1*
1University of Tampere, Institute of Medical Technology and Tampere University Hospital, Tampere, Finland, 2Gladstone Institute of Virology and Immunology,
University of California San Francisco, San Francisco, California, United States of America
Abstract
Background: Mammals have seven NAD-dependent protein deacetylases. These proteins, called sirtuins, are homologous to
yeast Sir2, and are emerging as important regulators of lifespan and intermediary metabolism. Three mammalian sirtuins,
SIRT3-5 are mitochondrial. Sirtuins are highly conserved between species, yet mouse SIRT3 was reported to be markedly
shorter than its human counterpart and to lack the N-terminal mitochondrial targeting signal present in the human protein.
Results: We have isolated a novel mouse SIRT3 splice variant. This cDNA contains two translation initiation codons upstream
of the originally reported start site. We show, using immunofluorescence and protein expression analysis that these longer
variants are expressed and efficiently targeted to mitochondria, and that the processed forms of these longer variants are
identical in size to the endogenous mouse SIRT3. We also show that the previously described form of SIRT3 is not
mitochondrial.
Conclusions: Our observations point to a high level of conservation of SIRT3 as a mitochondrial protein in mice and human
and indicate that several previous studies, which addressed mouse Sirt3 function, need to be re-evaluated.
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Introduction
The yeast ‘silent information regulator’ Sir2 is an NAD-
dependant deacetylase with a role in regulating longevity in
response to nutrient availability [1]. Members of the Sir2 family
are conserved from yeast to man and regulate metabolic
responses in several organisms. Seven Sir2-homologs have been
identified in humans and three of these sirtuins, SIRT3, SIRT4
and SIRT5 are targeted to mitochondria [2]. The mouse
counterparts of human SIRT3, 4 and 5 (mSIRT3, 4, 5) also
show mitochondrial localization [3,4,5]. The human SIRT3
(hSIRT3) deacetylates the mitochondrial acetyl-CoA synthetase,
AceCS2 [6,7], and, in human, SIRT3 and, in mouse, both
SIRT3 and SIRT4, interact with glutamate dehydrogenase
[5,8,9]. SIRT3, 4 and 5 knock-out mice show no evident
phenotype, except for hyperacetylation of mitochondrial proteins
in the absence of SIRT3 [5]. Curiously, and unexpectedly for a
mitochondrial protein, over-expression of mSIRT3 in mouse
adipocytes led to increased expression of several mitochondria-
related proteins such as uncoupling protein UCP1, and to an
increase in cellular respiration [3].
Despite a high degree of conservation between the mouse and
human sirtuins, the reported mouse SIRT3 cDNA encodes a
protein that lacks most of the mitochondrial targeting signal
present in the human protein. Questions whether SIRT3 is truly
mitochondrial [10] and whether the existing mSIRT3 cDNA is
complete have therefore been raised.
We set out to look for novel transcripts of mSIRT3. An in
silico analysis of mSIRT3 cDNA sequences predicted the
presence of a splice variant that introduces two potential
translational start sites [11] upstream of the one described
previously [3,12]. These potential start sites Met1 and Met15,
correspond to Met1 and Tryp15, respectively, in the human
SIRT3 gene. Here we describe the localization and proteolytic
processing of the newly predicted proteins from cDNAs cloned
from mouse 3T3 cells and compare their subcellular localization
to the protein expressed from the existing mSIRT3 cDNA. In
3T3 cells and primary mouse hepatocytes the two longer
mSIRT3 isoforms M1 and M2, beginning from Met1 and
Met15, respectively, are mitochondrial and are both proteolyt-
ically processed to a form that corresponds in size to
endogenous mSIRT3. The previously reported mSIRT3 iso-
form, which was over-expressed in mouse adipocytes, and was
previously reported to be mitochondrial [3], shows a distinct
cytoplasmic distribution that is not consistent with mitochondrial
localization. Moreover, it is shorter in size than the endogenous,
processed mSIRT3.
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The mSIRT3 isoform predicted by Yang et al., [12] and used in
over-expression studies by Shi et al., [3] begins from a methionine
codon corresponding to position 143 in the human SIRT3 amino
acid sequence. This implies that the mouse SIRT3 protein is
significantly shorter than its human counterpart. In a previous
study [11], we questioned the mitochondrial localization of this
truncated protein, examined the available mSIRT3 sequence data
and found evidence of a SIRT3 splice variant that included two
potential translational start sites at Met1 and Met15, correspond-
ing to Met1 and Tryp15 of the human SIRT3 gene. Here, using a
specific oligo that overlapped with the mSIRT3 stop codon, we
made cDNA from polyA RNA isolated from mouse NIH3T3
fibroblasts. Subsequent PCR and cloning using the same reverse
oligo and a forward oligo complementary to the region of exon 1B
containing the predicted M1 start codon [11] yielded 2 distinct
cDNAs. These two cDNAs are distinguished by the insertion of an
additional 8 bp at the 59extremity of exon 2 in splice variant 2
(Figure 1). This 8 bp is present in the originally suggested major
mRNA/cDNA suggested by Yang et al., [12]. It would
theoretically induce a frameshift in the translation of mSIRT3
initiated at the level of either Met 1 or Met 15 resulting in
termination of translation at codon 66. In our hands, cloning and
sequencing of 17 randomly selected cDNA clones yielded 9 clones
without the 8 bp insertion (Genbank accession FJ621493), thus
coding for the predicted full length protein, while 8 clones had the
8 bp insertion predicted to cause premature termination at codon
66. These findings suggest that at least in 3T3 cells both splice
variants were present in roughly equal proportions.
To further study the different mSIRT3 proteins encoded by
these different cDNAs, we generated three constructs. Two distinct
constructs were generated from splice variant 1 using in the first
case Met1, and in the second case Met15 as the initiation codon
(primers 1F and 2F, Figure 1). The third construct was generated
from splice variant 2 but using primer 1F (see Fig. 1). It thus
included the Met 1 and Met15 initiation codons as well as the
frameshift sequence leading to termination at codon 66.
Translation from the mRNA of the splice variant 2 construct
should yield an mSIRT3 protein which starts at the equivalent of
the human Met143 (mSIRT3 Met78) and lacks a mitochondrial
leader peptide. The protein products encoded by the three
constructs will hereafter be referred to as M1, M2 and M3,
respectively (see also Fig. 1). All three constructs included a 39 in
frame sequence for the FLAG epitope-tag.
To determine the subcellular localization of the different
mSIRT3 isoforms, we used immunofluorescence in transiently
transfected cells. Both M1 and M2 showed clear mitochondrial
localization in 3T3 cells (Fig 2 a,b), which was further confirmed
by co-staining with MitotrackerH Red. Despite the presence of two
ATGs followed by a stop codon at position 66, the M3 construct
generated a protein, which was detected using the FLAG
antiserum. This would indicate that the cDNA encoded a protein
starting at the third methionine. The protein encoded by this
construct, called M3, showed a non-mitochondrial uniform
cytosolic and sometimes nuclear staining with some clusters in
case of (rare) high levels of over-expression (Fig 2c). Based on the
immunofluorescence, M3 was generally expressed at lower levels
than M1 and M2 and a much lower number of cells could be
identified as clearly positive. We conclude that the proteins M1
and M2, starting from translational start sites at Met1 and Met15,
respectively, yield proteins that are mitochondrial, whereas the
shorter M3, which is the previously predicted full-length mouse
Sirt3 protein, is not targeted to mitochondria.
Figure 1. Schematic representation of the coding sequence of mSIRT3 splice variants. Met1 (M1) and Met15 (M2) are in exon 1B (E1B)
(nomenclature according to Yang et al., [12]), Met78 (M3, equivalent to M143 in hSIRT3) in exon 2 (E2). M1 and M2 were cloned from cDNA derived
from mouse NIH3T3 cells using exon 1B specific forward primers (1F and 2F in picture) and a reverse primer that included the sequence for the FLAG
epitope-tag, binding at exon 7. Similarly, the second splice variant that can only result in an mSIRT3 protein when translation initiates at the third ATG
(for M3) was obtained using the 1F and reverse oligo. Predicted proteins M1, M2 and M3 are indicated with a wave-line.
doi:10.1371/journal.pone.0004986.g001
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Western blot using either an antibody against the FLAG epitope
tag for the detection of over-expressed FLAG-tagged variants or
an antibody specific for mouse SIRT3 for the detection of
endogenous and over-expressed proteins. Human SIRT3 has
previously been shown to be cleaved into an enzymatically active
form by mitochondrial processing peptidase MPP [13]. Expression
from both the M1 construct (starting at Met1) and the M2
construct (starting at Met15) could be detected as 2 major forms:
an uncleaved precursor (indicated by arrows ‘M1’ and ‘M2’,
respectively) and an identical processed form (indicated by
‘proM1–2’), which corresponded in size to the endogenous protein
(including the epitope tag). This expression pattern was seen upon
over-expression in 3T3 cells (Fig 3A, right part for ‘endogenous
Kozak’), and was more clearly visible in mouse hepatocytes (Fig 3B)
as well as in human embryonal kidney (HEK) 293T cells (Fig 3C).
The M2 variant seemed to be processed more efficiently than M1.
This conclusion is based on the observation that the ratio of the
cleaved form versus the uncleaved precursor appeared higher for
M2 compared to M1 in all cell types examined. Especially in 3T3
and HEK293 cells, the precursor protein from the M2 construct
was often barely visible (see panels 3A and C) unless expression
was boosted by replacing the endogenous sequence upstream of
the start codon by a consensus Kozak sequence, as can be seen in
the left part of Figure 3A. Introduction of the consensus Kozak, in
particular into the M2 construct, helped to clearly identify the
precursor and cleaved form of the M2 protein in 3T3 cells. The
full-length M1-encoding vector also gave rise to a protein, which
was the same size as the precursor protein expressed from the M2-
encoding vector. This observation suggests that translation also
initiated at Met15 in the M1 construct; at low levels in 3T3 cells
and mouse hepatocytes but seemingly at much higher levels in
HEK293 cells. Accumulation of uncleaved precursor was also
clearly detected in human cells over-expressing full length hSIRT3
(Fig 4 and not shown), suggesting that this is not a peculiarity of
the mouse SIRT3 protein but rather something that SIRT3
proteins from various species have in common.
Detection of the M3 variant in total lysates and mitochondrial
fractions from 3T3 cells was weak at best (Fig 3A and Fig S1). This
is in agreement with the poor expression observed by immuno-
fluorescence. Detection was more clear in total lysates from mouse
hepatocytes and HEK293 cells (Fig 3B and C). The corresponding
human variant of the protein (translation from M143) was not
enriched in mitochondrial fractions and was shown to be non-
mitochondrial by immunofluorescence ([11], Fig. 4 and not
shown). The FLAG-tagged mSIRT3 M3 protein in mouse
hepatocytes migrated on SDS-PAGE as a single band which
was, despite the tag, smaller than endogenous (untagged) mSIRT3
(Figure 3B, compare bands indicated by ‘M3’ and ‘endogenous’
respectively). Furthermore, over-expression of non-tagged versions
of M1 and M2 in 293T cells showed processed proteins larger than
the FLAG-tagged M3 but identical in size to endogenous mouse
liver SIRT3. These results raise significant questions regarding the
physiological significance of the splice variant coding for the
mouse SIRT3 protein variant M3.
Sir2-orthologues are well conserved from yeast to man. The
identification of a mouse SIRT3 cDNA encoding a mSIRT3
protein significantly smaller than its human counterpart raised the
possibility that the reported [12] mouse SIRT3 cDNA was
incomplete. Careful analyses of available sequence data led to the
discovery of putative longer mSIRT3 transcripts. We have
confirmed our in silico findings [11] by cloning longer mSIRT3
Figure 2. Mouse SIRT3 variants M1 and M2 show mitochondrial localization, whereas M3 does not. Three FLAG-tagged mSIRT3 variants
M1, starting at Met1 (A), M2, starting at Met15 (B) and M3, starting at Met78 (C), were over-expressed in mouse 3T3 cells. Two days after transfection,
proteins were detected by immunofluorescence with an anti-FLAG antibody. The results show that M1 and M2 give a typically mitochondrial
localization pattern, upper panel (confirmed by MitotrakerH Red staining, lower panel). M3, on the other hand is more uniformly distributed in the
cytoplasm and does not show mitochondrial localization.
doi:10.1371/journal.pone.0004986.g002
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start sites and show here that the longer mSIRT3 variants, M1 and
M2 beginning at Met1 and Met15, respectively, are targeted to
mitochondria. M3, the previously predicted full length protein,
which begins at Met78 of the newly identified full length protein
M1, does not localize to mitochondria.
Interestingly, human SIRT3 does not have a methionine at
position 15, nor do other studied mammalian SIRT3 cDNAs.
Since we observed that translation using the M1 construct yielded
both the M1 and M2 precursor in varying amounts depending on
the cell type used (Fig 3), it is conceivable that the choice of the
mSIRT3 translation initiation site (Met1 vs. Met15) described here
serves a regulatory role resulting in the expression of proteins with
differing levels of proteolytic processing in mitochondria. Studying
the physiological consequences of over-expressing M1 and M2
may help in elucidating possible different physiological roles for
different SIRT3 forms.
Materials and Methods
Reagents and antibodies
All reagents used in this study were of analytical grade. Anti-c-
Myc 9E10 monoclonal antibody was purchased from Roche
Molecular Biochemicals. Anti-FLAG M2 monoclonal antibody
was purchased from Sigma. Anti-hSIRT3 was purchased from
Santa Cruz. Anti-mSIRT3 serum was homemade [5].
Cloning
Mouse NIH3T3 total RNA was isolated using Trizol reagent
(Invitrogen) and was enriched for polyA RNA using the OligotexH
kit (Qiagen). First strand cDNA synthesis (Superscript II kit,
Invitrogen) used an mSIRT3 specific oligo including a restriction
(NotI) and FLAG epitope sequence as follows: NotI/FLAG-
mSirt3R-59-GCA TGC GGC CGC TCA CTT ATC GTC GTC
ATC CTT GTA ATC TCT GTC CTG TCC ATC CAG C-39.
PCR amplification of cDNA used the NotI/FLAG-mSirt3R and
one of the following forward oligos to amplify cDNA from the M1
or M2 codon from within exon 1B (see Fig. 1 and main text):
HindIII-M1-mSirt3- 59-CTT AAG CTT ATT CGG ATG GCG
CTT GAC CC-39; HindIII-M2-mSirt3- 59-CTT AAG CTT
AGC ATC ATG GCG CTA AGC GG-39. PCR used standard
conditions with Pfu polymerase and the amplified cDNA was
initially cloned using Zero-blunt cloning (Invitrogen), and selected
clones partially sequenced to identify those cDNAs that did or did
not include the 8 bp extension to exon 2 (see Fig. 1). Fully
sequenced clones for both splice variants were subsequently
recloned into pcDNA5/FRT/TO (Invitrogen) using the HindIII/
NotI restriction sites. All subsequent recloning, e.g. to introduce a
consensus Kozak and/or stop codon used these original clones and
Figure 3. Over-expressed variants M1 and M2 appear in two
forms. FLAG-tagged mSIRT3 variants M1, M2 and M3 were expressed
in 3T3 cells (A) and primary mouse hepatocytes from both wild type
and ko-mice (B) while both FLAG-tagged M1–3 and untagged M1 and
M2 were expressed in HEK293T cells (C). Crude mitochondrial lysates
(3T3 cells, panel A) or total cell lysates (mouse hepatocytes and
HEK293T cells, panels B and C) were analysed by western blot with an
anti-FLAG antibody and an antibody against mSIRT3 as indicated in the
various panels. In an attempt to boost expression, all three variants
were also analyzed in 3T3 cells only, using constructs into which we
introduced a consensus Kozak sequence, 59CCACC (using PCR cloning),
immediately upstream the respective ATG for M1–3 (Left part of panel
A). A mouse liver extract was run alongside the HEK293T derived
samples (panel C) to denote the size of endogenous mSIRT3 (indicated
by R‘endogenous’). Similarly, non-transfected wild-type (wt) and
mSirt3 knock-out (ko) mouse hepatocytes were run along transfected
samples to clearly detect the endogenous protein (panel B, R‘endog-
enous’). In all cases both M1 and M2 constructs yielded an un-processed
precursor (indicated by RM1 and M2 for the FLAG tagged protein, and
RM1* and M2* for the untagged variants) and a processed mature
protein (indicated byRproM1–2, and RproM1*–2*), the latter corre-
sponding in size to the endogenous mSIRT3 (panel C). Translation of M2
but not M1 or M3, was greatly improved with the consensus Kozak
sequence (panel A). M2 was processed more efficiently than M1 (all
three panels). M2 processing may even account for all of the processed
over-expressed protein in M1 lanes, since the M1 construct was also
transcribed to yield a band the size of M2 in all cell types (all panels). In
each panel we have emphasized detected proteins using small dots
right from the appropriate bands. Over-expressed M3 is shorter than
endogenous mSIRT3 and was undetected or only weakly detected in
3T3 total cell lysates (Figure S1 and not shown) or 3T3 mitochondrial
lysates (panel A and not shown), but could clearly be detected in mouse
hepatocytes and HEK293 cells (panels B and C, indicated by RM3).
Membranes for total and mitochondrial 3T3 lysates were also analysed
for a control cytoplasmic and mitochondrial protein in particular to
illustrate the quality of the mitochondrial fractions (Figure S1).
doi:10.1371/journal.pone.0004986.g003
Mitochondrial Mouse Sirt3
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Cell culture and transfections
HEK293T cells and NIH3T3 cells were grown in DMEM
(Dulbecco’s modified Eagle’s medium) (Sigma) with 2 mM L-
glutamine (Cambrex Biosciences) and 10% FCS (foetal calf serum)
(Euroclone) unless stated otherwise. For immunofluorenscence
cells were transfected using Lipofectamine
TM2000 transfection
reagent (Invitrogen) according to the manufacturer’s instructions
and using 1 mg of DNA per well on a 6-well plate. For Western
blot analysis cells were similarly transfected using Lipofectami-
ne
TM2000 with 3 mg of DNA per 10 cm plate.
Mouse hepatocytes were isolated from H129sv male mice
according to a two-step collagenase perfusion technique described
by LeCluyse et al [14]. Briefly, the liver was flushed via the portal
vein with a calcium-chelating buffer for 3 to 5 min, followed by
perfusion with collagenase, for an additional 8 min. At the end of
the digestion, the liver was removed and transferred to a sterile
dish and minced thoroughly with scissors. Purified isolates
contained 88% hepatocytes. Purified hepatocytes in hepatocyte
plating medium containing 5% fetal bovine serum, insulin-
transferrin-selenium-G (16), 50 U/ml penicillin/streptomycin,
and 2 mM L-glutamine, were seeded onto culture dishes pre-
coated with collagen type I. Hepatocytes were allowed to attach at
37uC for 2 to 3 h in a humidified chamber gassed with 95% air
and 5% CO2 and transfected with different mouse SIRT3
expression constructs using Lipofectamine
TM2000. 24 hours after
transfection, cell lysates were prepared by directly adding 16SDS
sample buffer to the cells.
Animals
All animal experiments were carried out under protocols
approved by the Committee on Animal Research at the University
of California, San Francisco.
Immunofluorescence
For immunofluorescent detection, cells were grown on cover-
slips in 6 well plates. Following transfection for 1–2 days cells were
fixed using either 3.3% PFA (paraformaldehyde) in cell culture
medium for 25 min or in methanol for 5 min at 220uC [15]. This
was followed by three washes in PBS and lysis for 10 min with
0.5% Triton X-100 in PBS/10% FCS after PFA fixation. No lysis
step was performed after methanol fixation. Primary and
secondary antibodies were incubated at recommended concentra-
tions in PBS/10% FCS for 1 h or overnight. MitotrackerH Red
CMXRos treatment was performed prior to fixation essentially as
described previously [16]. Slides were mounted using ProLongH
Gold antifade with DAPI (4_,6- diamidino-2phenylindole; Invi-
trogen). Image acquisition using confocal microscopy was carried
out as described [17], using an Andor iXon DV885 EMCCD
camera and the Andor iQ software (Andor). Images were further
processed using Photoshop CS2.
Western Blotting
After detaching NIH3T3 cells and HEK293T cells were
isolated by centrifugation (1200 rpm for 2 min at +4uC) and
washed once with ice-cold PBS. For isolation of crude mitochon-
drial fractions by hypotonic lysis and differential centrifugation,
the cell pellet was resuspended by gentle pipetting in 2–3 vol of ice-
cold homogenization buffer [4 mM Tris/HCl (pH 7.8), 2.5 mM
NaCl, 0.5 mM MgCl2 and 0.1 mM PMSF], kept on ice for 6 min,
then homogenized in a glass homogenizer with 20–25 strokes of a
tight-fitting pestle. Disruption of the cells was monitored by
microscopy. A one-ninth volume of 106homogenization buffer
was added following lysis and nuclei and cell debris were pelleted
by centrifugation at 1200 g for 3 min at 4uC. Mitochondria from
the post-nuclear supernatants were recovered by centrifugation at
12000 g for 3 min at 4uC. Mitochondrial pellets were washed
once with 1 ml of ice-cold PBS and the mitochondrial pellet was
lysed 15 min on ice in 50 mM Tris/HCl (pH 7.5), 150 mM NaCl,
1 mM EDTA and 1%Triton X-10. An equal volume of 26
Laemmli sample buffer was added and the sample was denatured
at 95uC for 5 min prior to SDS/PAGE. Western blot analysis by
ECL (enhanced chemiluminescence) was performed essentially as
Figure 4. Human SIRT3 corresponds in its expression pattern
to mSIRT3. Full length (fl) MycHis (Myc) and FLAG tagged versions of
hSIRT3, or a truncated MycHis tagged version starting at Met143 (M3 in
mouse) were expressed in human HEK293 EBNA cells and crude
mitochondrial fractions were prepared for Western blot analysis using
an hSIRT3 antibody. The results show that the truncated version is only
weakly detected in the mitochondrial fraction in agreement with its
mostly cytoplasmic localization [11]. Over-expression of the full length
proteins shows the clear presence of both the precursor and mature
forms of hSIRT3.
doi:10.1371/journal.pone.0004986.g004
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broad-range markers from Fermentas. Peroxidase-coupled sec-
ondary anti-mouse and anti-rabbit antibodies were obtained from
Vector Laboratories. In some instances the SupersignalH West
Femto Maximum kit (Pierce) was used for detection according to
the manufacturer’s protocol. Detection and quantification used a
Bio-Rad Chemi Doc XRS system.
Supporting Information
Figure S1 FLAG-tagged mSIRT3 variants M1, M2 and M3
expressed in 3T3 cells. (A) Similar amounts of total cell and crude
mitochondrial lysates from cells expressing mSirt3 variants M1-3
from plasmids with endogenous Kozak sequences 59 of the
respective ATG start codons. (B) Samples from cells expressing
mSirt3 variants M1-3 from plasmids with consensus Kozak
sequences 59 of the respective ATG start codons. To illustrate
the quality of mitochondrial lysates, membranes were reprobed to
detect the cytosolic marker protein gamma-Actin (polyclonal
antibody from Novus Biologicals) and the mitochondrial marker
protein subunit I of cytochrome c oxidase (COXI, monoclonal
antibody from Invitrogen). These results illustrate the poor
expression of the M3 variant in 3T3 cells as it is not clearly
visible in mitochondrial nor in total cell lysates. The only modest
enrichment of the mSirt3 proteins in the mitochondrial lysates is
typical for transient over-expression of mitochondrial proteins.
Transient expression in our experience always results in a mosaic
of expressing cells with a considerable population of cells
expressing transgenes at such high levels that they show cytosolic
clustering (reminiscent of inclusion body formation in bacterial
expression) and aberrant targeting. Marked arrows are as in
Figure 3.
Found at: doi:10.1371/journal.pone.0004986.s001 (0.08 MB
PDF)
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